EvansMDS

A funding initative of the Edward P. Evans Foundation

EDWARD P. EVANS FOUNDATIONCONTACT
  • ABOUT MDS
    • ABOUT MDS
    • RESOURCES
    • EDWARD P. EVANS
  • FUNDING MDS RESEARCH
    • FUNDING MDS RESEARCH
    • RESEARCHER PROFILES
    • FUNDING INFORMATION
    • CENTERS FOR MDS
  • EVANS MDS SUMMIT
  • LEADERSHIP
    • BOARD OF TRUSTEES
    • SCIENTIFIC ADVISORY BOARD
  • CONTACT
  • EDWARD P. EVANS FOUNDATION

Hall, Trent, PhD

Researcher Profiles

Researcher Profiles

<BACK TO ALL RESEARCHERS

Trent Hall, PhD

Trent Hall, PhD

St. Jude Children’s Research Hospital

2026 Funding recipient

Identifying Novel Regulators of Leukemic Progression in GATA2 Deficiency Syndrome

EvansMDS Young Investigator Award 2026

PROJECT SUMMARY

GATA2 deficiency is a rare, inherited genetic syndrome found in children that arises from mutations in GATA2, which is a gene that is critical for proper blood development. These mutations result in a non-functional protein, which can lead to improper immunity and myelodysplastic syndrome (MDS). MDS is a disorder in which the bone marrow does not produce enough healthy blood cells and can often progress to acute leukemia. Unfortunately, 75% of patients with GATA2 deficiency develop blood disorders, including MDS, by early adulthood. To study this disease, I created a mouse model with a common GATA2 deficiency mutation, Gata2R396Q. These mice express a mutated form of GATA2 in every cell of their body, including blood cells. I also created a line of human cells expressing GATA2R396Q that can be used to model disease in the human setting. I use my mouse and human models to 1.) Determine the effects of GATA2 deficiency on normal blood development and 2.) Explore how GATA2 deficiency leads to MDS and acute leukemia. To do this, I am tracking the complexity of the blood system in Gata2R396Q mice and pairing other mutations found in GATA2 deficiency-related leukemia with my mouse and human models to identify regulators of disease progression. These studies provide new insights into the biology of GATA2 deficiency and will facilitate development of novel therapies to prevent or treat related blood disorders.

  • ABOUT MDS
  • FUNDING MDS RESEARCH
  • EVANS MDS SUMMIT
  • LEADERSHIP
  • CONTACT
  • EDWARD P. EVANS FOUNDATION

Copyright © 2026 Evans MDS
Site Credits

  • ABOUT MDS
    • ABOUT MDS
    • RESOURCES
    • EDWARD P. EVANS
  • FUNDING MDS RESEARCH
    • FUNDING MDS RESEARCH
    • RESEARCHER PROFILES
    • FUNDING INFORMATION
    • CENTERS FOR MDS
  • EVANS MDS SUMMIT
  • LEADERSHIP
    • BOARD OF TRUSTEES
    • SCIENTIFIC ADVISORY BOARD
  • CONTACT
  • EDWARD P. EVANS FOUNDATION